Live Breaking News & Updates on Surg case

Stay informed with the latest breaking news from Surg case on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Surg case and stay connected to the pulse of your community

Man experiences gradual onset of blurry vision in pseudophakic eye

Man experiences gradual onset of blurry vision in pseudophakic eye
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Jeffrey-chang , Jonathant-caranfa , Angell-shi , Allison-resnik , Tufts-university-school-of-medicine , England-eye-center , Surg-case , Cataract-refract , New-england-eye-center , Tufts-university-school ,

Will Immunotherapy Work as Salvage Therapy for Patients with Testicular Germ Cell Tumors?

Published 01 March 2021
It’s now been 3.5 years since I last wrote anything about testicular germ cell tumors and ongoing clinical trials.
1 Although we still cure most men afflicted with this disease, we have not made any major new therapeutic advancements since I wrote that last article. Approximately, 15-20% of patients with metastatic germ cell tumors will relapse following initial chemotherapy. Even in this situation, approximately 50% can still be cured with salvage treatments, either with more conventional cisplatin-based chemotherapy or with high-dose chemotherapy and autologous stem cell rescue.
2-4 However, patients with cisplatin-refractory disease or progressive disease following high-dose salvage chemotherapy and autologous stem cell rescue, harbor an extremely dim prognosis. In these situations, palliative chemotherapy, with regimens containing oxaliplatin, is limited in efficacy, and targeted biologic therapies have also shown limited efficacy.

Germany , Fred-hutchinson-cancer-research-center , Washington , United-states , University-of-washington , Seattle , German , Evan-yu , Clinical-research-division , Clinical-research-service , Seattle-cancer-care-alliance , Clinical-research